Summary The combination of high-dose folinic acid with 5-fluorouracil has shown improved response rates in several trials in advanced colorectal carcinoma. This however is at the expense of increased toxicity: regimens using weekly bolus injections produce diarrhoea in most patients and occasional toxic deaths from this, whilst those using daily injections for one week in four report both diarrhoea and severe oral mucositis. Both types of regimen have significant rates of myelosuppression.
Several trials have recently demonstrated that the administration of high-dose folinic acid can enhance the efficacy of 5-fluorouracil used in the treatment of advanced adenocarcinomas of gastrointestinal origin: phase III studies have shown improved response rates and survival in colorectal cancer (Erlichman et al., 1988; Petrelli et al., 1988; Poon et al., 1989) although gastric cancer has been less widely studied. One phase II trial showed a response rate of 48% (Machover et al., 1986 ) but another only 12% (Arbuck et al., 1987) and a third 24% (Berenberg et al., 1989) . These reports also describe toxicity different from that produced by 5-fluorouracil alone: Regimens using weekly bolus injections are reported as frequently causing diarrhoea (in 22-80% of patients) with occasional toxic deaths from this (Petrelli et al., 1988; Petrelli et al., 1989) , whilst those employing daily injections for one week in four report both diarrhoea and oral mucositis -the latter in 40-80% of patients (Machover et al., 1986; Erlichman et al., 1988; Poon et al., 1989) . Both types of regimen show significant rates of myelosuppression with neutropenia in 10-50% of patients.
A recent report (De Gramont et al., 1988) (Siefert et al., 1975; Lokich et al., 1989) and phase I trials showed the maximum tolerated dose to be up to four times greater if a continuous infusion is used rather than repeated bolus doses (Lokich et al., 1981) .
The cytotoxicity of 5-fluorouracil shows a steep dose-response relationship so that the use of continuous infusions to increase the maximum tolerated dose may be expected to improve response rate relative to toxicity. A phase II study was therefore undertaken using the same programme, but also incorporating allopurinol mouthwashes with the intention to reduce oral toxicity as reported previously (Clark & Slevin, 1985) . 
Patients and methods

Sixty
Chemotherapy
The treatment was given as: Folinic acid 200 mg m-2 by IV infusion over 2 h in 5% Dextrose, then 5-Fluorouracil 400 mg m-2 IV bolus, then 5-Fluorouracil 400 mg m-2 by IV infusion over 22 h in 5% Dextrose. This was repeated over the next 24 h. The schedule was given every 2 weeks for up to 12 courses depending upon the response.
Allopurinol mouthwashes (Clark & Slevin, 1985) at a strength of 1 mg ml-' were used hourly for the first 4 h after the 5-Fluorouracil bolus and 4-hourly thereafter for 48 h. Analysis by primary site shows a response rate in colorectal tumours of 24% (95% CI 11-37%) and in gastric tumours of 40% (95% CI 10-70%). No responses were seen in pancreatic tumours. The median duration of remission was 6.4 months and median survival for the whole group 17.3 months.
There was no significant difference in pre-treatment performance status between responders and non-responders. Performance status rose following the start of treatment in 60% of patients, and 70% reported a subjective improvement in overall well-being. Three hundred and eighty-six courses of treatment (median five per patient) were evaluated for toxicity. No toxicity greater than WHO Grade II was seen. Nine per cent of courses were associated with some oral mucositis and 12% with some diarrhoea. Only nine (3%) treatments were delayed by neutropenia (absolute neutrophil count less than 1.5 x 1091-') and no febrile neutropenic episodes occurred.
Forty-six per cent of patients reported some nausea and 25% vomiting, but this was frequently present before the start of treatment owing to abdominal tumour masses. Anti-emetics were not prescribed prophylactically solely for chemotherapy. Six patients developed a hand-foot syndrome during treatment. This was usually seen after at least four cycles of treatment and responded to pyridoxine at a dose of 150 mg/ day as described in a recent report (Mortimer & Anderson, 1989) .
Rates of toxicity using this regimen are compared with others previously reported in Figure 1 . 
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Discussion
These results confirm that it is possible to give an effective regimen of 5-fluorouracil and high-dose folinic acid with little toxicity. Although the dose-intensity of the schedule (800-mgm-2 week-' of 5-FU) is considerably higher than that used by others (450-460 mg m2 week-') the frequency with which diarrhoea and oral mucositis occur are greatly reduced and myelosuppression is not a problem at all. There was no necessity for dose reductions and 97% of treatments were given as planned. The response rate seen was in accord with those obtained in other colorectal cancer studies (De Gramont et al., 1988; Petrelli et al., 1988; Petrelli et al., 1989; Poon et al., 1989; Machover et al., 1986; Erlichman et al., 1988; Arbuck, 1989) , suggesting similar efficacy, although clearly a phase III trial would be required to confirm this. The response rate in gastric cancers is comparable to that described for more toxic combination regimens (Macdonald et al., 1979; Gastrointestinal Tumor Study Group 1982; Douglass et al., 1984) and considerably better than that reported previously for 5-fluourouracil and folinic acid (Arbuck et al., 1987; Berenberg et al., 1989) . Although the numbers treated are small it certainly appears worthy of further evaluation. The use of allopurinol mouthwashes in preventing oral mucositis is now the subject of a randomised trial.
It is clearly of great importance that chemotherapy given with purely palliative intent should have as few adverse effects as possible. Although shown to be effective against colorectal adenocarcinomas the combination of high-dose folinic acid and 5-fluorouracil has not been widely used up to now because of previous reports of severe toxicity and only modest activity in gastric cancers. 5-fluorouracil when given by infusion is known to be better tolerated than bolus doses, but the coincident use of folinic acid poses the problem of obtaining adequate levels of both drugs at the same time.
(An extracellular reduced folate concentration of 10 ILmol 1-' is required for optimal inhibition of thymidylate synthetase in culture studies (Evans et al., 1981) ). A 50% bolus loading dose of 5-fluorouracil immediately after the folinic acid is therefore used to produce high levels of the drug coincident with the highest levels of reduced folate, whilst the following TM Mz3=.s infusion maintains their effect. This may be expected to improve cytotoxicity whilst maintaining tolerability. That admission to hospital is required for 48 h every fortnight is a disadvantage, but the lack of toxicity once at home is considerable compensation for this. There are advantages over a schedule of daily injections for 5 consecutive days which often necessitates admission to hospital for logistic reasons such as the distance patients may be obliged to travel. If this schedule were to be widely adopted consideration could be given to the use of indwelling venous access devices for the administration of treatment by portable infusion pumps.
Thus it is felt that this regimen achieves a useful therapeutic balance, limiting toxicity but retaining anti-tumour activity. It should now be evaluated in a phase III trial against the 'standard' 5-fluorouracil/folinic acid regimens.
